Blood Biomarkers for Return to Play after Concussion in Professional Rugby Players

International audienceWe prospectively evaluated a panel of seven blood biomarkers (S100B, NSE, SBDP, UCHL1, GFAP, NFL, and Tau) for sport-related concussion (SRC) in a large multicentric cohort of 496 professional rugby players from 14 French elite teams. Players were sampled twice during the season (beginning and end) away from any sport practice. From these two baseline samples, we evaluated the intra-individual variability to establish the effect of rugby on blood biomarkers over a season. Only S100B and GFAP remained stable over the course of a season. During the period of the study, a total of 45 SRC cases was reported for 42 players. In 45 SRCs, the head injury assessment (HIA) process was performed and blood collection was realized 36 hours after the concussion (HIA-3 stage). For each biomarker, raw concentrations measured 36 hours after SRC were not significantly different between players with a non-resolutive SRC (n=28) and those with a resolutive SRC (n=17) (p between 0.06 and 0.92). In a second step, blood concentrations measured 36 hours after SRC were expressed according to the basal concentrations as an individual percentage change (PCH36[%]), calculated as follows: PCH36 = 100 x (([Biomarker]36h - [Biomarker]basal) / [Biomarker]basal). S100B and NFL concentrations expressed as PCH36[%] were significantly different between non-resolutive and resolutive SRCs (p=0.006 and 0.01 respectively), with a positive delta found in non-resolutive SRCs. Among the two biomarkers, it is important to note that only the S100B protein was stable during the season. In the context of our study, during HIA-3 assessment, S100b seems to perform better than NSE, SBDP, UCHL1, GFAP, NFL, and Tau as biomarker for SRC. From a clinical standpoint, the S100B modification over baseline may be valuable, at 36 hours after concussion to distinguish non-resolutive SRC from resolutive SRC